14
Participants
Start Date
September 15, 2021
Primary Completion Date
May 25, 2023
Study Completion Date
May 25, 2023
Ustekinumab
Participants will receive IV infusion and SC injection of ustekinumab.
Placebo
Participants will receive IV infusion and SC injection of matching placebo.
Glucorticoid Taper Regimen
Glucocorticoid will be administered orally.
Tokyo Medical and Dental University Hospital, Bunkyō City
Chiba University Hospital, Chiba
Kyushu University Hospital, Fukuoka
Hamamatsu University Hospital, Hamamatsu
Saitama Medical University Hospital, Iruma-gun
Kagawa University Hospital, Kita Gun
Kobe University Hospital, Kobe
Kyoto University Hospital, Kyoto
Matsuyama Red Cross Hospital, Matsuyama
Nagoya City University Hospital, Nagoya
Niigata University Medical And Dental Hospital, Niigata
Okayama University Hospital, Okayama
Kitano Hospital, Osaka
Rinku General Medical Center, Osaka
Kindai University Hospital, Osaka Sayama Shi
Kitasato University Hospital, Sagamihara
Sapporo Medical University Hospital, Sapporo
Hokkaido University Hospital, Sapporo
Tohoku University Hospital, Sendai
Center Hospital of the National Center for Global Health and Medicine, Shinjuku Ku
National Cerebral and Cardiovascular Center, Suita-Shi
Mitsui Memorial Hospital, Tokyo
St. Luke's International Hospital, Tokyo
Fujita Health University Hospital, Toyoake
University of Tsukuba Hospital, Tsukuba
Wakayama Medical University Hospital, Wakayama
Tottori University Hospital, Yonago
Lead Sponsor
Janssen Pharmaceutical K.K.
INDUSTRY